[go: up one dir, main page]

DE69230491D1 - Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren - Google Patents

Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren

Info

Publication number
DE69230491D1
DE69230491D1 DE69230491T DE69230491T DE69230491D1 DE 69230491 D1 DE69230491 D1 DE 69230491D1 DE 69230491 T DE69230491 T DE 69230491T DE 69230491 T DE69230491 T DE 69230491T DE 69230491 D1 DE69230491 D1 DE 69230491D1
Authority
DE
Germany
Prior art keywords
cells
virus
retrovirus
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230491T
Other languages
English (en)
Other versions
DE69230491T2 (de
Inventor
David Klatzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie
Original Assignee
Universite Pierre et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie filed Critical Universite Pierre et Marie Curie
Publication of DE69230491D1 publication Critical patent/DE69230491D1/de
Application granted granted Critical
Publication of DE69230491T2 publication Critical patent/DE69230491T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69230491T 1991-10-30 1992-10-30 Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren Expired - Fee Related DE69230491T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9113429 1991-10-30
PCT/FR1992/001017 WO1993008844A1 (fr) 1991-10-30 1992-10-30 Cellules transformees pour la prevention ou le traitement de maladies induites par des virus, notamment retrovirus pathogenes

Publications (2)

Publication Number Publication Date
DE69230491D1 true DE69230491D1 (de) 2000-02-03
DE69230491T2 DE69230491T2 (de) 2000-08-03

Family

ID=9418480

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230491T Expired - Fee Related DE69230491T2 (de) 1991-10-30 1992-10-30 Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren

Country Status (7)

Country Link
EP (1) EP0564645B1 (de)
JP (1) JPH06505401A (de)
AT (1) ATE188124T1 (de)
CA (1) CA2099247A1 (de)
DE (1) DE69230491T2 (de)
ES (1) ES2142834T3 (de)
WO (1) WO1993008844A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
AU1257495A (en) * 1993-11-18 1995-06-06 Chiron Corporation Compositions and methods for utilizing conditionally lethal genes
WO1995030007A1 (en) * 1994-05-02 1995-11-09 University Of Washington Thymidine kinase mutants
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
FR2736931B1 (fr) 1995-07-17 1997-09-19 Univ Paris Curie Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures
ITTO20100633A1 (it) 2010-07-21 2012-01-21 Cnh Italia Spa Meccanismo operativo per un cavo bowden

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
FR2606030B1 (fr) * 1986-10-31 1989-10-20 Pasteur Institut Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
WO1989009271A1 (en) * 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
FR2629469B1 (fr) * 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
WO1990011359A1 (en) * 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
FR2651005B1 (fr) * 1989-08-17 1992-01-03 Pasteur Institut Lignees de cellules infectables par un retrovirus et contenant un marqueur activable a l'occasion de l'infection
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy

Also Published As

Publication number Publication date
CA2099247A1 (fr) 1993-05-01
ES2142834T3 (es) 2000-05-01
JPH06505401A (ja) 1994-06-23
ATE188124T1 (de) 2000-01-15
EP0564645A1 (de) 1993-10-13
DE69230491T2 (de) 2000-08-03
WO1993008844A1 (fr) 1993-05-13
EP0564645B1 (de) 1999-12-29

Similar Documents

Publication Publication Date Title
MY138860A (en) Hiv protease inhibitors.
EA199901031A1 (ru) Производные бензимидазола
ATE199718T1 (de) Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate- aufnahme
DE69230491D1 (de) Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ES2182915T3 (es) Procedimiento de purificacion del factor viii
GR900100481A (el) Μέ?οδος παρακευής υδατικού αιωρήματος για ουσιαστικά αδιάλυτους στο νερό ενεργούς παράγοντες.
EP0270317A3 (de) Pharmaceutische Zuberatung zur Behandlung von Virus-Krankheiten
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
DK249287A (da) Stof eller farmaceutisk praeparat eller kosmetisk praeparat, der haemmer eller oedelaegger mindst et encellet, levende vaesen og/eller mindst et virus, laegemiddel eller produkt indeh. et saadant stof, fremgangsmaade til fremstilling af et saadant stof, kemiskforbindelse indeh. et saadant stof og fremgangsmaadetil inhibering eller oedelaeggelse af mindst et encellet, levende vaesen og/eller mindst et virus
FR2388828A1 (fr) 5-iodo-5'-amino-2',5'-didesoxycytidine et medicament contenant cette substance ou un sel de celle-ci
FR2388562A1 (fr) Medicament contenant de la 5'-amino-5'-desoxythymidine ou un sel de cette substance
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ATE88752T1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
ATE155795T1 (de) Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
DE59310242D1 (de) Verwendung von Mangan-Superoxiddismutase (Mn-SOD) zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen in niedriger Dosierung
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE189604T1 (de) Extrakte von piliostigma thonningii, deren verwendung und diese enthaltende zubereitungen
DE69434019D1 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung
RU92009797A (ru) Дезинфицирующий водный раствор для стоматологических оттисков

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee